Pao W - Search Results

1

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, Shyr Y, Camidge DR, Sequist LV, Glisson BS, Khuri FR, Garon EB, Pao W, Rudin C, Schiller J, Haura EB, Socinski M, Shirai K, Chen H, Giaccone G, Ladanyi M, Kugler K, Minna JD, Bunn PA. Kris MG, et al. Among authors: pao w. JAMA. 2014 May 21;311(19):1998-2006. doi: 10.1001/jama.2014.3741. JAMA. 2014. PMID: 24846037 Free PMC article. Clinical Trial.

2

Characteristics of lung cancers harboring NRAS mutations.

Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, Camidge DR, Vnencak-Jones CL, Berry L, Pan Y, Sasaki H, Engelman JA, Garon EB, Dubinett SM, Franklin WA, Riely GJ, Sos ML, Kris MG, Dias-Santagata D, Ladanyi M, Bunn PA Jr, Pao W. Ohashi K, et al. Among authors: pao w. Clin Cancer Res. 2013 May 1;19(9):2584-91. doi: 10.1158/1078-0432.CCR-12-3173. Epub 2013 Mar 20. Clin Cancer Res. 2013. PMID: 23515407 Free PMC article.

3

Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas.

Pan Q, Pao W, Ladanyi M. Pan Q, et al. Among authors: pao w. J Mol Diagn. 2005 Aug;7(3):396-403. doi: 10.1016/S1525-1578(10)60569-7. J Mol Diagn. 2005. PMID: 16049312 Free PMC article.

4

Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma.

Marks JL, Broderick S, Zhou Q, Chitale D, Li AR, Zakowski MF, Kris MG, Rusch VW, Azzoli CG, Seshan VE, Ladanyi M, Pao W. Marks JL, et al. Among authors: pao w. J Thorac Oncol. 2008 Feb;3(2):111-6. doi: 10.1097/JTO.0b013e318160c607. J Thorac Oncol. 2008. PMID: 18303429 Free article.

5

EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression.

Li AR, Chitale D, Riely GJ, Pao W, Miller VA, Zakowski MF, Rusch V, Kris MG, Ladanyi M. Li AR, et al. Among authors: pao w. J Mol Diagn. 2008 May;10(3):242-8. doi: 10.2353/jmoldx.2008.070178. Epub 2008 Apr 10. J Mol Diagn. 2008. PMID: 18403609 Free PMC article.

6

Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond.

Ladanyi M, Pao W. Ladanyi M, et al. Among authors: pao w. Mod Pathol. 2008 May;21 Suppl 2:S16-22. doi: 10.1038/modpathol.3801018. Mod Pathol. 2008. PMID: 18437168 Free article. Review.

7

Integration of molecular profiling into the lung cancer clinic.

Pao W, Kris MG, Iafrate AJ, Ladanyi M, Jänne PA, Wistuba II, Miake-Lye R, Herbst RS, Carbone DP, Johnson BE, Lynch TJ. Pao W, et al. Clin Cancer Res. 2009 Sep 1;15(17):5317-22. doi: 10.1158/1078-0432.CCR-09-0913. Epub 2009 Aug 25. Clin Cancer Res. 2009. PMID: 19706816

8

Genetically informed lung cancer medicine.

Pao W, Iafrate AJ, Su Z. Pao W, et al. J Pathol. 2011 Jan;223(2):230-40. doi: 10.1002/path.2788. Epub 2010 Oct 25. J Pathol. 2011. PMID: 21125677

9

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M, Riely GJ. Yu HA, et al. Among authors: pao w. Clin Cancer Res. 2013 Apr 15;19(8):2240-7. doi: 10.1158/1078-0432.CCR-12-2246. Epub 2013 Mar 7. Clin Cancer Res. 2013. PMID: 23470965 Free PMC article.

10

Acquired resistance to TKIs in solid tumours: learning from lung cancer.

Camidge DR, Pao W, Sequist LV. Camidge DR, et al. Among authors: pao w. Nat Rev Clin Oncol. 2014 Aug;11(8):473-81. doi: 10.1038/nrclinonc.2014.104. Epub 2014 Jul 1. Nat Rev Clin Oncol. 2014. PMID: 24981256 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

243 results

Search Page